Renal and cardiovascular protection in type 2 diabetes mellitus: Angiotensin II receptor blockers

Journal of the American Society of Nephrology

Volumn 13, Issue SUPPL. 3, 2002, Pages

  Deferrari, Giacomo ^a   Ravera, Maura ^a   Deferrari, Luca ^a   Vettoretti, Simone ^a   Ratto, Elena ^a   Parodi, Denise ^a  

^a Department of Internal Medicine ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALDOSTERONE; AMLODIPINE; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IRBESARTAN; PLACEBO; RENIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CELL PROTECTION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG CHOICE; DRUG EFFICACY; ENZYME INHIBITION; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; META ANALYSIS; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REHABILITATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0036841352     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (53)

1. Parving HH, Osterby R, Ritz E: Diabetic nephropathy. In: The Kidney, edited by Brenner BM, Philadelphia, W.B. Saunders, 2000, pp 1731-1773
2. Viberti GC, Walker JD, Pinto J: Diabetic nephropathy. In: International Textbook of Diabetes Mellitus, edited by Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, New York, John Wiley & Sons Ltd., 1992, pp 1267-1328
3. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 276: 1886-1892, 1996
4. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 340: 677-684, 1999
5. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317: 703-713, 1998
6. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351: 1755-1762, 1998
7. Kaplan NM: Management of hypertension in patients with type 2 diabetes mellitus. Guidelines based on current evidence. Ann Intern Med 135: 1079-1183, 2001
8. Mogensen CE, Keane WF, Bennet PH, Jerums G, Parving HH, Passa P, Steffes MW, Striker GE, Viberti GC: Prevention of diabetic renal disease with special reference to microalbuminuria. (Consensus report). Lancet 346: 1080-1084, 1995
9. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 157: 2413-2446, 1997
10. Feldman RD: The 1999 Canadian Recommendations for the Management of Hypertension. On behalf of the Task Force for the Development of the 1999 Canadian Recommendation for the Management of Hypertension. Can J Cardiol 15SG: 57G-64G, 1999
11. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J: For the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am J Kidney Dis 36: 646-661, 2000
12. Kjeldsen SE, Erdine S, Farsang C, Sleight P, Mancia G: The 1999 WHO/ISH Hypertension Guidelines Subcommittee, 1999. WHO/ISH Hypertension Guidelines-highlights & ESH update. J Hypertens 20: 153-155, 2002
13. American Diabetes Association: Treatment of hypertension in adults with diabetes. Diabetes Care 25: 199-201, 2002
14. Deferrari G, Cavallo Perin P, Di Paolo S, Locatelli R, Nosadini R, Penno G, Piccoli G, Ravera M: Linee guida della nefropatia diabetica. Giornale Italiano di Nefrologia, 2002, in press
15. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, De Jong PE, De Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS for the AIPRD Study Group: Proteinuria as a modifiable risk factor for the progression of non diabetic renal disease. Kidney Int 60: 1131-1140, 2001
16. Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS Jr, Rovin BH: Renoprotection One or many therapies? Kidney Int 59: 1211-1226, 2001
17. Parving HH: Renoprotection in diabetes: Genetic and non genetic risk factors and treatment. Diabetologia 41: 745-759, 1998
18. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 27: 2033-2039, 1996
19. Dinh DT, Frauman AG, Johnston CI, Fabiani ME: Angiotensin receptors: Distribution, signalling and function. Clin Sci 100: 481-492, 2001
20. Hollenberg NK: Renal implications of angiotensin receptors blockers. AJH 14: 237S-241S, 2001
21. Hollenberg NK: Non-insulin-dependent diabetes mellitus, nephropathy, and the renin system. J Hypertens Suppl 15: S7-S13, 1997
22. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001
23. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
24. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
25. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118: 577-581, 1993
26. Sano T, Hotta N, Kawamura Tm Matsumae H, Chaya S, Sasaki H, Nakayama M Hara T, Matsuo S, Sakamoto N: Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: Result of a 4-year, prospective, randomized study. Diabet Med 13: 120-124, 1996
27. Ahmad J, Siddiqui MA, Ahmad H: Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 20: 1576-1581, 1997
28. The Microalbuminuria Captopril Study Group: Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 39: 587-593, 1996
29. Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F, Spalluto A, Vanasia A, Villa GM, Nosadini R, The Italian Microalbuminuria Study Group in IDDM: Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care 21: 104-110, 1998
30. Penno G, Chaturvedi N, Talmud PJ, Cotroneo P, Manto A, Nannipieri M, Luong L, Fuller J, the Euclid Study Group: Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ace inhibition in IDDM patients. Findings from the EUCLID randomized controlled trials. Diabetes 47: 1507-1511, 1998
31. Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving HH: Randomised controlled trial of long term efficacy of captopril on preservation of Kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ 319: 24-25, 1999
32. The ATLANTIS Study Group: Low dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension. Diabetes Care 23: 1823-1829, 2000
33. Voyaki SM, Staessen JA, Thijs L, Wang JG, Efstratopoulos AD, Birkenhager WH, de Leeuw PW, Leonetti G, Nachev C, Rodicio JL, Tuomilehto J, Fagard R, Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. J Hypertens 19: 511-519, 2001
34. Estacio RO, Jeffers BW, Gifford N, Shrier R: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23[Suppl 2]: B54-B64, 2000
35. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355: 253-259, 2000
36. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, Schwartz SL, Mengel MC, Segal R, Versaggi JA: Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria. Kidney Int Suppl 45: S150-S155, 1994
37. Chan JC, Ko GT, Leung DH, Cheung RC, Cheung MY, So WY, Swaminathan R, Nicholls MG, Critchley JA, Cockram CS: Long term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 57: 590-600, 2000
38. Baba S, The J-Mind Study Group: Nifedipine and enalapril equally reduce the progresion of nephropathy in hypertensive type 2 diabetics. Diab Res 54: 191-201, 2001
39. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50: 1641-1650, 1996
40. Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH: Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 46: 1182-1188, 1997
41. Fogari R, Zoppi A, Corradi L, Mugellini A, Lazzari P, Preti P, Lusardi P: Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 13: 47-53, 1999
42. Deferrari G, Cheli V, Robaudo C: Treatment of diabetic nephropathy in its early stages. Diabetes/Metab Rev 13: 51-61, 1997
43. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993
44. Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M: Renal protective effect of enalapril in diabetic nephropathy. Br Med J 304: 339-343, 1992
45. Elving LD, Wetzels JF, van Lier HJ, de Nobel E, Berden JH: Captopril and atenolol are equally effective in retarding the progression of diabetic nephropathy. Diabetologia 37: 604-609, 1994
46. Tarnow L, Rossing P, Jensen C, Hansen BV, Parving HH: Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 23: 1725-1730, 2000
47. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH: Progression of diabetic nephropathy. Kidney Int 59: 702-709, 2001
48. Sica DA, Douglas JG: The African American Study of Kidney Disease and Hypertension (AASK): New findings. J Clin Hypertens 3: 244-251, 2001
49. Hansson L: Recent intervention trials in hypertension initiated in Sweden-HOT, CAPPP and others. Hypertension Optimal Treatment Study. Captopril Prevention Project. Clin Exp Hypertens 21: 507-515, 1999
50. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21: 597-603, 1998
51. Lindholm LH, Hansson L, Ekbom T, Dahlof B, Lanke J, Linjer E, Schersten B, Wester PO, Hedner T, de Faire U: Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: Results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 18: 1671-1675, 2000
52. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317: 713-726, 1998
53. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, The LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): A randomised trial against atenolol. Lancet 359: 1004-1010, 2002